drugset / Trial / NCT03818581
Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes
RandomizedCrossoverDouble-blindTreatment
Summary
The investigators aim to determine the effect of suvorexant on subjective total sleep time (TST) in suboptimally controlled Type 2 diabetics with chronic insomnia in a randomized placebo-controlled trial for 3 months.
Timeline
- Start
- 2019-03-15
- Primary completion
- 2021-11-03
- Completion
- 2021-11-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Suvorexant | Small molecule | 10 mg | — |
| Comparator | Suvorexant | Small molecule | 20 mg | — |